Yana Samsudin expecting fourth child at 41
4 Jun - It was just last year that she gave birth to her third child, and now Yana Samsudin revealed that she will be welcoming her fourth child.
The 41-year-old actress confirmed the good news recently, saying that her fourth child is expected to be born in October.
"This time, it is less challenging than when I was pregnant with the third one. For the third one, I couldn't even get up for six months. But this time, I am able to do work," she said.
As for how far long she has been, Yana, who suffered from PCOS, said that the pregnancy is entering its fifth month.
"With my third child, I prayed to God to be given a fourth child and He granted my wish. It really is my dream to have lots of kids," she said.
To avoid any risks considering she is pregnant at the age of 41, Yana said she also made early preparations by having a non-invasive prenatal test (NIPT).
Yana and her husband, Fadzil Zahari tied the knot in 2015. They are blessed with three children, Aisy Mateen, 8, Aura Aisy Sofea, 4, and Hakeem, 1.
(Photo Source: Yana Samsudin IG)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
8 hours ago
- Washington Post
Need advice? Join columnist Carolyn Hax's weekly chat (June 13
Advice columnist Carolyn Hax takes your comments and questions most Fridays about life, family, relationships and more. Some questions may be adapted into full columns, and transcripts of the chats remain available after each session concludes. Here's a glossary of frequently used chat terms. Read transcripts from past live chats here. The question box includes a space for your name, but this is optional. Your submissions are anonymous unless you choose to identify yourself. To reply to other posts, simply include 're:' or 'to' the topic in the subject line of your post. Sign up here to receive an email right as the chat is about to start.
Forbes
17 hours ago
- Forbes
Why Women's Health Research Still Lags Behind
Woman chemist testing for gender differences. The gender gap in healthcare isn't just a question of equity—it's a question of evidence. For too long, women have been excluded from clinical trials, overlooked in preclinical research, and underserved by healthcare systems. The consequences are both deeply personal and widely systemic: Women are more likely to be misdiagnosed, experience adverse drug reactions, and face delays in care. 'It's like death by a thousand paper cuts,' said Alisa Wilson, managing director at Accenture, in a recent interview. 'We're tackling this problem piecemeal, when what's needed is a holistic overhaul across the entire healthcare ecosystem.' New research from Accenture and Springboard Enterprises, 2025 State of Women's Health, sheds light on just how pervasive these gaps are—and what it will take to close them. Bias starts early and compounds over time. Preclinical research—the scientific foundation for nearly all therapies—is still dominated by male models. Animal studies, cell lines, and early-phase drug testing frequently rely on male subjects, based on the outdated assumption that male data is 'universal.' The result? Research hypotheses, safety profiles, and drug mechanisms are skewed from the start. Source: Accenture and Springboard 2025 State of Women's Health That bias continues into clinical trials. Even when women are included, they are often underrepresented or excluded from subgroup analyses. Women made up only 29% of heart attack clinical trial participants, even though heart disease is the number one killer of women globally, according to Accenture's analysis of data from 2020 to 2024. Women also represent just 60% of autoimmune trial participants, even though they make up about 80% of people with autoimmune conditions. 'There's a clear lack of sex-specific data,' said Miranda Ewald, director of programs at Springboard. 'When women are included in research, their outcomes are often not analyzed separately. That makes it impossible to understand how diseases or treatments affect them differently.' Lack of sex-specific dosing, unequal access to optimal treatments and unique challenges to ... More medication contribute to women's poorer health outcomes Even before a clinical trial is an option, women face significant hurdles in getting a diagnosis. On average, it takes up to 7 years to be diagnosed with conditions like polycystic ovarian syndrome (PCOS) or endometriosis. These delays are often dismissed as stress, aging, or psychosomatic symptoms. Despite biological differences, drug dosing rarely accounts for sex. Amani Bright, senior program manager at Springboard, emphasizes the importance of empathy in solving this problem. 'We need decision-makers—funders, policymakers, and healthcare systems—to understand how long and frustrating the patient journey is until they are diagnosed and treated correctly. Women are being left behind because their symptoms don't fit the outdated mold.' That frustration is not limited to patients. Healthcare innovators are also encountering barriers. 'Even with strong scientific validation, women's health startups still face real hurdles—like undefined regulatory pathways and unclear reimbursement models,' said Alice Zheng, partner at Foreground Capital. 'That slows everything down.' Despite these barriers, a new wave of innovators is reimagining how healthcare can better serve women. Companies are working to correct historical research bias by designing more inclusive clinical trials, often in partnership with patient advocacy groups and underrepresented communities. They're also thinking creatively about data collection. 'We're seeing startups use virtual consent tools and culturally sensitive materials to boost trial participation,' said Bright. 'And they're considering real-world factors like language, caregiving responsibilities, and transportation needs.' But to truly accelerate progress, innovators need more support from the healthcare establishment. 'When we worked with a major life sciences client, it took two years just to integrate sex-based thinking into their R&D pipeline,' said Wilson. 'They had never considered sex differences at the discovery stage. That's how deeply ingrained the male-default model is.' Emerging technologies, such as artificial intelligence (AI) and machine learning, offer promise in shortening the research-to-treatment gap. 'We saw how fast COVID vaccines came to market when urgency and collaboration aligned,' said Wilson. 'AI can do the same for women's health if we commit to using high-quality, inclusive data.' However, there is a caveat here as well. AI models trained on biased datasets will only perpetuate the problem. 'To leverage AI effectively, we need to ensure that data is disaggregated by sex, race, and age,' said Wilson. 'Only then can we track adverse events accurately, tailor dosage by gender, and improve safety and efficacy for all patients.' Part of the problem, all interviewees agree, is definitional. When many people hear 'women's health,' they think of reproductive health—fertility, contraception, and menopause. Those areas deserve investment, but they are just one part of a much larger picture. 'The market opportunity is not just the uterus,' said Bright. 'Women's health includes cardiovascular, autoimmune, mental health, and cognitive aging—all areas where women are differently or disproportionately impacted.' Zheng echoed this: 'If we think women's health only means OB-GYN, we're missing the big picture. Breast cancer, for example, is often called a 'solved' disease—but for women with dense breast tissue, early screening is still inadequate.' Fixing the gender gap in medicine requires systemic change. That includes: Most importantly, it requires the healthcare system to see women not as a special case, but as a default patient. The women's health gap is not a niche issue—it's a symptom of centuries of systemic neglect that continues to hinder progress in women's health innovation. When women are misdiagnosed, overlooked, or excluded from research, the entire healthcare system suffers. 'We don't need another pilot program,' said Wilson. 'We need full-scale transformation—led by research, powered by investment, and centered on the real-life experiences of women.' Advancing women's health research and innovation starts with closing the data gap—and ultimately, closing the outcomes gap.
Entrepreneur
18 hours ago
- Entrepreneur
Manila-Based telehealth Startup &you Secures Pre- Seed Funding from International Investors
The company is launching with a focus on some of the most neglected and misunderstood health issues in Southeast Asia. But its broader ambition is to become the region's most seamless and trusted online healthcare platform — a market expected to surpass $22 billion by 2030, growing at a CAGR of over 18%. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media. &you ( a health tech startup founded by entrepreneur Emil Eriksen, has raised an undisclosed amount in pre-seed funding, backed by a strategic group of early investors in a round led by New York-based VC Everywhere Ventures. "Despite a dynamic global trade environment, the macro tailwinds behind Southeast Asia and the Philippines in particular are unquestionable. We believe in rising prosperity, the incredible power of an expanding middle class, and the demand that creates for quality healthcare products. We are excited to be investing in the Philippines for the fifth time," said Scott Hartley, co-founder and managing partner, Everywhere Ventures. The company is launching with a focus on some of the most neglected and misunderstood health issues in Southeast Asia. But its broader ambition is to become the region's most seamless and trusted online healthcare platform — a market expected to surpass $22 billion by 2030, growing at a CAGR of over 18%. Rebuilding Healthcare Starts with Restoring Trust In the Philippines, trust in the healthcare system is in short supply — and for good reason. Ninety percent of people self-medicate, not by choice but out of necessity. Seven in ten rural patients travel hours just to see a specialist. Half of Filipinos can't reach a clinic within 30 minutes, and 50% of families face financial hardship just trying to access basic care. For millions, traditional healthcare is either out of reach, unaffordable, or unreliable. That's the gap &you is stepping into — not just with technology, but with a new model built around clinical credibility, licensed care, and patient trust. Tech at its core — not layered on later While a few players already exist in the space, &you believe the current offerings fall short — especially in markets like the Philippines, where patients are often left with overpriced products, clunky apps, or worse: black-market alternatives. &you offers licensed doctor consultations and FDA-compliant treatments through a streamlined digital platform — no clinic visits required. &you is developing a fully localized end-to-end system — from mobile onboarding and medical intake to prescription and nationwide delivery — built specifically for Southeast Asia's infrastructure and behavior. The platform will use advanced technology to help users assess their health and connect them with licensed local doctors to create personalized treatment plans. "We're addressing unique regional challenges such as disrupted supply chains, user- unfriendly platforms, and a significant trust deficit. Our goal is to make getting help feel as easy and safe as ordering food," said Emil Eriksen, Founder of &you. A Homegrown Model with Global Standards Behind the scenes, &you works only with FDA-compliant partners and fully-licensed doctors, ensuring that all treatments are not only accessible but also safe and fully regulated. The company emphasizes user experience and clinical credibility — not just cheaper medicine. All &you orders are handled through carefully selected partners to ensure a smooth and confidential delivery experience. Early Traction Signals Big Demand Since launching just this April, &you has already seen rapid traction, with thousands of customers in the few month, and expects to scale quickly as awareness grows. The new funding will be used to scale engineering, expand local operations, and prepare for entry into new verticals in the next 12 months. "Healthcare doesn't work here the way it should," Eriksen says. "We're fixing that — one problem, one product, and one person at a time."
